In an assessment of trigger point dry needling as a treatment for orchialgia, an analysis of self-reported improvement data from 2009 to 2016, as well as NIH Chronic Prostatitis Symptom Index (NIH-CPSI) data, showed that 85% of patients who underwent pelvic floor trigger point dry needling as a component of physical therapy (PT) indicated their orchialgia improved.
To evaluate the benefit of physical therapy for orchialgia in previously treated patients, researchers conducted a retrospective review of patient data for men who underwent pelvic floor PT after going through other treatments, including non-steroidal anti-inflammatory drugs, antibiotics, surgery, nerve block, narcotics, and previous pelvic floor PT. Results showed an improvement in NIH-CPSI pain and quality of life categories for all patients who received previous orchialgia treatment.
A randomised controlled study of 108 patients with prostatitis, but without erectile dysfunction, evaluated the efficacy and safety of a daily low dose tadalafil added to levofloxacin for the treatment of chronic prostatitis/chronic pelvic pain syndrome.
The study concluded low dose tadalafil added to levofloxacin as treatment is well tolerated and significantly improved chronic prostatitis/chronic pelvic pain syndrome related symptoms.
The AUA, an advocate for the specialty of urology, has more than 21,000 members throughout the world. The association encourages scientific research, education and formulation of health care policy in the field of urologic medicine.
LEO Pharma advances delgocitinib cream into phase 3 trial for lichen sclerosus
HistoIndex partners Houston Research Institute
Formosa Pharmaceuticals licenses APP13007 ophthalmic therapy to Samil for South Korea
Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial
Elanco Animal Health's Befrena (tirnovetmab) receives USDA approval for canine dermatitis
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
Alvotech launches first-in-market golimumab biosimilar in Europe
Physiomics secures follow-on UK contract for Phase 2 study support
RedHill Biopharma reports positive opaganib data in venetoclax-resistant CLL
InduPro secures strategic investment and collaboration with Sanofi to advance autoimmune therapy
Innovent Biologics reports first participant dosed in Phase 1 trial of IBI3011